Description
Royalty Pharma’s Latest Acquisition Targets A $7 Billion Market!
Royalty Pharma plc has expanded its development-stage portfolio by acquiring part of Neurimmune’s royalty interest in AstraZeneca’s cliramitug, committing up to $425 million for a 3% to 4% royalty on worldwide net sales. The structure includes $125 million upfront, another $125 million scheduled for the first quarter of 2027, and $175 million tied to clinical and regulatory milestones. Cliramitug is a Phase 3, first-in-class antibody designed to remove transthyretin amyloid fibrils from the hearts of patients with ATTR cardiomyopathy, rather than only slowing further protein accumulation. Results from the DepleTTR-CM study are expected in 2028, placing the investment in Royalty Pharma’s development pipeline. The deal follows a strong first quarter, when portfolio receipts rose 10%, royalty receipts increased 13%, and management highlighted growing use of structured royalty funding.
